Artivion Inc. Common Stock (AORT)
Fast GrowerFairStock Score: 39/100 — MIXED
Key Financials
| Current Price | $22.77 |
| Market Cap | $1.8B |
| P/E Ratio | 91.08 |
| ROE | 3.14% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Revenue growth of 19.2% demonstrates strong top-line momentum
Concerns
- Trades significantly above Graham Number ($7) with negative 461% margin of safety—limited downside protection
AI Analysis
Artivion Inc. Common Stock is a micro-cap healthcare company valued at $1.8 billion. The business generates $441 million in annual revenue with a 0.5% net margin. From a quality standpoint, Artivion shows Altman Z-Score of 2.9 in the grey zone and modest 3% ROE. On valuation, the stock is commanding a steep 176.9x multiple, with trades far above its Graham Number ($7) with no margin of safety. Growth dynamics show revenue growing at 19.2% and profit growth of 114.7%. Our composite FairStock Score of 39/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Artivion's 19% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
At 177x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer